8. Safety, immunogenicity and preliminary efficacy of a randomized clinical trial of omicron XBB.1.5-containing bivalent mRNA vaccine.

Xuanjing Yu# ; Wei Yang# ; Wei Li; Na Wan; Guanghong Yan; Zumi Zhou; Xiao Zhu; Wei Su; Yani Li,; Chenyu Xing; Sifan Duan; Houze Yu; Xinshuai Zhao; Chunmei Li; Taicheng Zhou*; Dingyun You*; Jia Wei*; Zijie Zhang*

  hLife  2024

7. Clinicopathological and immunological features of new onset kidney disease: a rare event after SARS-CoV-2 vaccination

Yue-Miao Zhang, Xing-Zi Liu, Zhao Zhang, Tai-Cheng Zhou, Xin Zhang, Hong-Yu Yang, Meng Tan, Nan Hu, Su-Fang Shi, Fang Wang, Rong Xu, Li-Jun Liu, Su-Xia Wang, Gang Liu, Fu-De Zhou, Ming-Hui Zhao, Hong Zhang, Ji-Cheng Lv*, Ya-Ping Zhang*, Zi-Jie Zhang*, Li Yang*

  National Science Review  2023

6. ​​​​​Long-term and effective neutralization against omicron sublineages elicited by four platform COVID-19 vaccines as a booster dose

Yuemiao Zhang, Meng-Ting Luo, Qingqin Wu, Yun-Xia Wang, Xupu Ma, Guanghong Yan, Si-Hang Zhang, Yanli Chen, Na Wan, Liang Zhang, Dingyun You, Jia Wei*, Zijie Zhang*, Tai-Cheng Zhou* & Precise-CoVaccine study group

  Cell Discovery  2023

5. Dynamics of immune responses to inactivated COVID-19 vaccination over 8 months in China

Tianpei Shi, Mu-Xian Dai, Feng-Wei Liu, Jun Hu, Mu-Hua Feng, Gang-Xu Xu, Ya-Jing Wang, Li-Hong Zhang, Liang Zhang, Zijie Zhang*, Tai-Cheng Zhou*, Jia Wei*; on be half of the Precise-CoVaccine study group

  Journal of Infection  2023

4. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled phase 2 trial

Yuemiao Zhang#, Xupu Ma#, Guanghong Yan#, Ying Wu#, Yanli Chen, Zumi Zhou, Na Wan, Wei Su, Feng-Wei Liu, Mu-Xian Dai, Mei Yang, Chunmei Li, Xuanjing Yu, Liang Zhang, Zhongfang Wang, Tai-Cheng Zhou, Dingyun You, Jia Wei*, Zijie Zhang* on behalf of the Precise-CoVaccine study group

  eClinicalMedicine  2022

3. Retrospective study of the immunogenicity and safety of the CoronaVac SARS-CoV-2 vaccine in people with underlying medical conditions

Chunmei Li*, Hanfang Bi, Zhenwang Fu, Ao Li, Na Wan, Jun Hu, Fan Yang, Tai-Cheng Zhou, Yupeng Liang, Wei Su, Tianpei Shi, Mei Yang, Rong Wang, Wanting Qin, Xuanjing Yu, Hong-Yi Zheng, Zumi Zhou, Yong-Tang Zheng, Jia Wei, Gang Zeng*, Zijie Zhang* & the Precise-CoVaccine study group

  Communications Medicine  2022

2. ​​​​​A third dose of inactivated SARS-CoV-2 vaccine induces robust antibody responses in people with inadequate response to two-dose vaccination

Taicheng Zhou*, Tianpei Shi, Ao Li, Lingzhi Zhu, Xinshuai Zhao, Naiyin Mao, Wanting Qin, Hanfang Bi, Mei Yang, Muxian Dai, Fengwei Liu, Rong Wang, Wei Su, Liang Zhang, Wenbo Xu, Jia Wei*, Zijie Zhang*

  National Science Review  2022

1. ​​​​​Immunosuppression impaired the immunogenicity of inactivated SARS-CoV-2 vaccine in non-dialysis kidney disease patients

Yue-Miao Zhang, Xing-Zi Liu, Miao-Miao Lin, Jin-Can Zan, Yi-Tong Hu, Xiang-Qiu Wang, Wen-Qi Wu, Tai-Cheng Zhou, Ji-Cheng Lv, Hong Zhang, Li Yang*, Zi-Jie Zhang*

  Journal of Infection  2022